bioAffinity Technologies, Inc.
NASDAQ Capital MarketCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Maria Zannes
- Full Time Employees
- 57
- Sector
- Healthcare
- Industry
- Medical - Diagnostics & Research
- Address
- 22211 West Interstate 10 San Antonio TX United States of America 78257
- IPO Date
- Sep 1, 2022
- CIK
- 0001712762
- Website
- bioaffinitytech.com
- Similar Companies
- Business
- bioAffinity Technologies, Inc. (NASDAQ: BIAF) develops noninvasive diagnostics for early-stage lung cancer and other lung diseases using flow cytometry and automated analysis; it also advances targeted cancer therapeutics through its subsidiary OncoSelect Therapeutics. The company offers CyPath Lung, a laboratory-developed test that analyzes sputum samples with a porphyrin molecule to detect cancer cells via fluorescence, marketed through its wholly owned subsidiary Precision Pathology Laboratory Services, LLC (PPLS) to high-risk patients following suspicious low-dose CT findings; additional pipeline efforts target diagnostics for other cancers and lung conditions like COPD via porphyrin-based flow cytometry, alongside broad-spectrum therapeutics that selectively kill cancer cells in preclinical stages. Founded in 2014 and headquartered in San Antonio, Texas, bioAffinity Technologies operates in the United States within the biotechnology and in vitro diagnostics industry, serving physicians, veterans' healthcare, and high-risk patient populations. In September 2023, the company acquired PPLS, boosting 2024 laboratory revenues toward $9.4 million with over 20% annualized growth and a 1,750% rise in CyPath Lung sales through November versus the prior year; recent achievements include securing reimbursement for CyPath Lung, gaining federal healthcare access, expanding the sales team, and streamlining operations ahead of national market rollout; bioAffinity closed a $4.8 million public offering in September 2025 via WallachBeth Capital to fund technology development.
Multidisciplinary Physician Panel to Share Real-World Benefits of bioAffinity Technologies' Noninvasive CyPath Lung Cancer Test in Upcoming Society for Advanced Bronchoscopy Webinar
bioAffinity Technologies Announces Notification of Mexico Patent Allowance Covering Novel Lung Cancer Detection Methods Using CyPath® Lung Technology
bioAffinity Technologies Reports Record Monthly CyPath® Lung Unit Sales and Significant Year-Over-Year Growth in April 2026
bioAffinity Technologies Reports First Quarter 2026 Results and Expanding Adoption and Clinical Usage of CyPath® Lung
bioAffinity Technologies Launches New Study To Expand Use of CyPath® Lung Technology for Asthma and COPD Diagnosis and Treatment
bioAffinity Stock Surges 113.8% in 3 Months: What's Driving the Rally?
New Case Study: bioAffinity Technologies' CyPath® Lung Diagnostic Supports Physician's Assessment, Prompts Follow-Up Imaging and Defers Unnecessary Biopsy
bioAffinity Technologies, Inc. (BIAF) Discusses Clinical Integration of CyPath Lung in Pulmonary Nodule Assessment and Early Lung Cancer Diagnosis Transcript
bioAffinity Technologies' CyPath® Lung to Be Featured at Cleveland Clinic Annual “Advances in Early Lung Cancer Detection” Symposium April 16
bioAffinity Technologies' CyPath® Lung Test Unit Sales Surged 146% Year-Over-Year in Q1 2026
bioAffinity Technologies to Host Live Virtual Physician Roundtable on Integrating CyPath® Lung into Pulmonary Practice
bioAffinity Technologies (BIAF) Projected to Post Quarterly Earnings on Monday
New Case Study: bioAffinity Technologies' CyPath® Lung Provides Actionable Results and Helps Patient Avoid Costly, Invasive Procedures
bioAffinity Technologies Stock Cools Off After Strong Friday Rally - Here's Why
bioAffinity Technologies Stock Soars 120% On CyPath Lung Sales Growth
bioAffinity Technologies Announces Record 2025 Revenue and Unit Sales for Flagship Lung Cancer Diagnostic CyPath® Lung
bioAffinity Technologies Announces Initiation of Large-Scale Longitudinal Clinical Study for Its Noninvasive CyPath® Lung Cancer Diagnostic
BIAF vs. GH: Which Cancer Detection Stock Is the Better Buy Now?
bioAffinity Technologies Presents Positive Research Findings for its Novel Diagnostic Platform Technology to Identify Optimal Therapies for Asthma Patients
bioAffinity Technologies Announces Validation Study with Brooke Army Medical Center to Expand Sample Collection Options for the CyPath® Lung Noninvasive Early Detection Lung Cancer Test